Cipla USA, the wholly owned subsidiary of Cipla (established in 1935), has been enabling patient access to affordable and high-quality medicines in the US for over 30 years. The company brings a wealth of pharmaceutical experience to the US and provides innovative generic products and advanced drug delivery systems that offer meaningful healthcare solutions to patients in the country. As a pioneer in inhalation therapy/respiratory care, Cipla ranks no. 2 in inhaler sales globally and ranks in the top 3 for US generic respiratory sales. Cipla has invested more than $1 billion dollars in the US with offices and manufacturing plants located in Warren, NJ; Hauppauge, LI; and Fall River, MA, employing nearly 800 people. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in home markets of India, South Africa, North America, and key regulated and emerging markets. The company's strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments are well-known. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders.